Through a search of electronic health records from the IKnowMed clinical oncology database (McKesson, Houston, TX, USA) the ...

In recognition of September as Prostate Cancer Awareness Month, Daniel Petrylak, MD, professor of oncology and urology at ...

Plixorafenib (FORE 8394; PLX8394) with or without cobicistat (Tybost) demonstrated a clinical benefit and differentiated duration of response in patients with MAPK inhibitor-naive thyroid cancer ...

The FDA has granted fast track designation to the antibody-drug conjugate (ADC) CRB-701 for the treatment of recurrent or ...

Cabozantinib, a tyrosine kinase inhibitor (TKI), was recently approved for patients with previously treated pancreatic NETs.

Researchers explore innovative macrocyclic peptides to target small cell lung cancer, revealing promising therapeutic ...

Ligufalimab receives FDA orphan drug designation for AML, showcasing promising efficacy and safety in treating hematologic ...

The US FDA has granted breakthrough therapy designation to the novel antibody-drug conjugate (ADC) raludotatug deruxtecan ...

Kidney injury molecule–1 (KIM-1) has emerged as a potential prognostic biomarker for response to therapy and could be used to ...

During a live event, Kit Yu Lu, MD, discussed data on antibody-drug conjugates in HR+, HER2- breast cancer including the ...

Pierre Gholam, MD, observes the improvements in outcomes with lenvatinib seen in recent trials of unresectable hepatocellular carcinoma compared with the original phase 3 REFLECT trial.

During a live event, Raajit K. Rampal, MD, PhD, discussed ropeginterferon's potential to reduce JAK2 allele burden in ...